Changes in A1C and Body Weight by Subgroup in Patients With Type 2 Diabetes in DURATION-8

April 19, 2018. DURATION-8 (Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention With Exenatide Once Weekly) was a double-blind, phase 3, randomized controlled trial conducted in patients with type 2 diabetes (N=694). The trial assessed the efficacy at 28 weeks of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide plus the sodium-glucose cotransporter-2 (SGLT-2) dapagliflozin vs dapagliflozin alone or exenatide alone, all with background metformin therapy. Changes in A1C and body weight were evaluated according to subgroup characteristics, including baseline A1C, sex, age, body mass index, race, ethnicity, and estimated glomerular filtration rate (eGFR). Across all subgroups, A1C and body weight were reduced in patients receiving exenatide plus dapagliflozin, with least‐squares mean reductions ranging from -0.77% to -2.39% for A1C and -2.07 to -4.55 kg for body weight. A1C reductions were greater among patients with eGFR ≥90 vs ≥60 to <90 mL/min/1.73 m2 in the exenatide plus dapagliflozin and dapagliflozin alone groups, but not with exenatide alone. Overall, in adequately sized subgroups, greater reductions in A1C and body weight were seen in patients treated with exenatide once weekly and dapagliflozin. You can read the study abstract here.